XtalPi Holdings has partnered with Singapore's A*STAR under the MARVEL-AI materials initiative. The company uses AI, robotics, and quantum physics to discover drugs and materials. The collaboration was announced on October 29, 2026 during Singapore Week of Innovation and Technology.
Partnership scope
MARVEL-AI is anchored by A*STAR's Institute of Materials Research and Engineering. It focuses on metal alloys, polymers, ceramics, and composites. The program aims to move discoveries into manufacturing for semiconductors, energy, and advanced chemicals.
Company background
XtalPi was founded in 2015 by three MIT physicists. It is listed on the Hong Kong Stock Exchange as 2228. It provides R&D solutions in pharmaceuticals, materials, agriculture, energy, chemicals, and cosmetics.
How the platform works
XtalPi combines computational predictions, agentic AI workflows, and robotic experimentation. The expanded partnership includes customized lab automation and joint research facilities. It also covers talent exchange to speed commercial translation.
XtalPi has worked with A*STAR's Experimental Drug Development Centre since 2022 on oncology therapies. The new agreement extends that work into advanced materials. Both groups plan to connect material validation with industrial use.